Respiratory Distress Syndrome In Premature Infants: A Retrospective Cohort Study From 14 Hospitals In China

Fengdan Xu,Xiangyong Kong,Shunyan Duan,Hongyan Lv,Rong Ju,Zhankui Li,Shujuan Zeng,Hui Wu,Xuefeng Zhang,Weipeng Liu,Fang Liu,Hongbin Cheng,Yanjie Ding,Tieqiang Chen,Ping Xu,Xiaomei Tong,Zhichun Feng
2019-01-01
Abstract:Objective: The aim of the current study was to investigate epidemiological characteristics of RDS in premature infants in China. Methods: A total of 13,701 premature infants, born in the Department of Neonatology of 14 hospitals from major cities in 11 provinces of China, between January 2013 and December 2014, were included. These infants were divided into the RDS group and non-RDS group. General conditions, perinatal factors, incidence of complications, and mortality rates were retrospectively analyzed. Results: The morbidity rate of RDS in premature infants was 15.7%. The mortality rate of premature infants with RDS was 8.7%. Increased gestational age (GA) and born weights (BW), as well as prenatal dexamethasone and para times >= 2, were protective indexes against RDS. Male gender, neonatal asphyxia, multiple pregnancies, cesarean deliveries, and placenta previa were significantly associated with RDS in premature infants. Of the premature infants, 5,485 (40%) received antenatal dexamethasone therapy. A total of 986 (56.0%) were preterm infants with GA < 32 weeks. Incidence of RDS in neonates with GA < 33 weeks in the antenatal corticosteroids group was lower, compared to the non-antenatal corticosteroids group. Conclusion: Mortality and morbidity rates of preterm neonates with RDS were higher than rates in those without RDS. Prenatal dexamethasone may effectively reduce incidence of RDS and improve prognosis in preterm neonates with GA < 33 weeks.
What problem does this paper attempt to address?